Structure Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Structure Therapeutics (GPCR).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

3S.Buy

13Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$98Upside to Avg. PT+112.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	Citigroup	Samantha Semenkow	PT Cut	Buy	$100→$97
Aug 7, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$113→$110
Jun 11, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$100→$70
Apr 27, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$101
Mar 16, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$114→$100
Mar 2, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$90→$114
Feb 27, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$120→$113
Jan 22, 2026	JP Morgan	Hardik Parikh	PT Raise	Overweight	$65→$105
Jan 20, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$90→$140
Dec 19, 2025	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$60→$90
Dec 12, 2025	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$120→$125
Dec 12, 2025	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$87→$120
Dec 11, 2025	Jefferies	Chris Howerton	PT Raise	Buy	$79→$125
Dec 9, 2025	Citigroup	Samantha Semenkow	PT Raise	Buy	$60→$100
Dec 9, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$50→$90
Dec 9, 2025	Clear Street	Kaveri Pohlman	PT Raise	Buy	$61→$99
Aug 7, 2025	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$75→$60
Aug 7, 2025	Guggenheim	Seamus Fernandez	PT Cut	Buy	$92→$90
Aug 7, 2025	JMP Securities	Jonathan Wolleben	PT Cut	Market Outperform	$89→$87
Jun 23, 2025	Cantor Fitzgerald	Prakhar Agrawal	Maintained	Overweight	$65

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.

Benzinga Newsdesk

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $70.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Buy rating and announces Price Target of $101.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $114 to $100.

Benzinga Newsdesk

Structure Therapeutics Inc

Structure Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100

People Also Watch

People Also Watch

Benzinga

Benzinga

Structure Therapeutics Inc

Structure Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

PROCitizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

PROHC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

PROCanaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

PROHC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100

People Also Watch

People Also Watch

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $100